^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    2d
    A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. (PubMed, Discov Oncol)
    In this retrospective, real-world study, the two regimens demonstrated comparable disease control, and the bi-weekly regimen appeared to be better tolerated, representing a reasonable potential alternative. Nevertheless, these findings should be interpreted as exploratory, and future prospective studies are warranted.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    2d
    Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • everolimus • pazopanib
    2d
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=75, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • temozolomide • pumitamig (BNT327)
    2d
    French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of advanced cervical cancer (PubMed, Bull Cancer)
    Since 2022, immunotherapy is part of standard therapeutic strategy with pembrolizumab on the one hand, associated with chemotherapy and bevacizumab in patients with PD-L1 positive tumors (CPS≥1), and cemiplimab on the other hand, in patients who did not receive prior immunotherapy and progress after first line regardless of PD-L1 expression. Whenever possible, molecular screening and determination of HER2 status may allow orienting patients to clinical trials. Indeed, inclusion in investigational studies must be systematically considered and early supportive care is always recommended.
    Clinical guideline • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc)
    3d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    Clinical study on the treatment of relapsed/refractory soft tissue sarcoma with liposome irinotecan combined with temozolomide and bevacizumab (ChiCTR2600117731)
    P=N/A, N=24, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Avastin (bevacizumab) • temozolomide
    3d
    Vitrectomy With or Without Conbercept for Proliferative Diabetic Retinopathy with Fibrovascular Membranes: A Prospective Randomized Controlled Trial (ChiCTR2600116843)
    P=N/A, N=160, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    3d
    Research Protocol for Primary Extracranial Origin Malignant Rhabdoid Tumor (eMRT-2025) (ChiCTR2600116480)
    P=N/A, N=105, Recruiting, Beijing Childrens Hospital,Capital Medical University; Beijing Childrens Hospital,Capital Medical University
    New trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Avastin (bevacizumab)
    3d
    Efficacy and Safety of Atezolizumab Combined with Bevacizumab and Local Therapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study (ChiCTR2500115061)
    P=N/A, N=1136, Not yet recruiting, Zhongda Hospital, Affiliated to Southeast University; Zhongda Hospital, Affiliated to Southeast University
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    Diabetic Macular Edema (DME) Patient Response to Faricimab and Associated Aqueous Humor Proteomic Differences Pre- and Post-Treatment (ChiCTR2500113982)
    P=N/A, N=154, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    3d
    Asingle-arm,open-label,multi-centerclinicalstudyofthecombinationofetotilizumabandanti-angiogenicdrugsand/orchemotherapyassecond-linetreatmentforpatientswithmetastaticcolorectalcancer. (ChiCTR2500113997)
    P=N/A, N=30, Not yet recruiting, Qingdao Traditional Chinese Medicine Hospital; Qingdao Traditional Chinese Medicine Hospital
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin
    3d
    Pioneer study: a prospective, single arm, exploratory clinical study of anti-pd-1/ctla-4 combination antibody combined with bevacizumab in the treatment of non squamous non-small cell lung cancer after immune resistance (ChiCTR2500112841)
    P=N/A, N=36, Recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK translocation
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab)